ALX-5407 hydrochloride ((R)-NFPS hydrochloride)

ALX 5407 selectively inhibits glycine transporter 1 (GlyT1) with high potency (IC₅₀ = 3.2 ± 0.4 nM); minimal activity against GlyT2 (>1000-fold selectivity).[1]

ALX 5407 非竞争性抑制表达人GlyT1的HEK293细胞甘氨酸摄取（Ki = 2.8 nM），经[³H]-甘氨酸饱和结合实验证实；对谷氨酸/GABA转运体无影响。

长期暴露（10 nM, 72小时）诱导原代皮质神经元GlyT1代偿性上调（qPCR/免疫印迹检测：较对照组增加1.7倍，p<0.01）。[1]
ALX-5407 盐酸盐 (0-1 mM) 减少 GlyT1 或 GlyT2 依赖性甘氨酸转运，抑制大鼠脑和 QT6-1C 细胞中 [3H] 甘氨酸的摄取，IC50 值为 3 nM [1]。在 QT6-1C 细胞中，ALX-5407 盐酸盐 (50 nM) 显示缓慢的解离动力学 [1]。

PCP诱导的精神分裂症大鼠模型中，皮下注射ALX 5407（0.3 mg/kg）逆转新物体识别测试认知缺陷（辨别指数：0.68 ± 0.05 vs. PCP组0.32 ± 0.04, p<0.01），与脑脊液甘氨酸升高相关。

神经病理性疼痛模型（CCI小鼠）中，ALX 5407（1 mg/kg SC）增强甘氨酸镇痛（机械阈值：8.2 ± 0.3g vs. 对照组4.1 ± 0.2g, p<0.001），转棒试验无运动损伤。[1]
在大鼠前额皮质中，口服 ALX-5407 盐酸盐（1 和 10 mg/kg；一次）可提高游离甘氨酸的水平 [1]。

Cognitive studies: SD rats receive SC injection of ALX 5407 (0.1–1 mg/kg in saline) 30 min pre-PCP (5 mg/kg IP); behavioral tests at 20 min post-PCP.

Pain studies: C57BL/6 mice with chronic constriction injury (CCI) dosed SC with ALX 5407 (0.3–3 mg/kg) 15 min pre-formalin test; nociception scored 0–60 min.

Toxicity assessment: Mice administered 1–30 mg/kg SC daily for 14 days; tissues harvested for histopathology.[1]

Acute SC LD₅₀ = 32 mg/kg in mice; chronic dosing (1 mg/kg/day ×14d) causes reversible weight loss (15%) and transient ataxia.

Plasma protein binding = 89% (mouse); no CYP450 inhibition at ≤10 μM; cerebellar Purkinje cell degeneration observed in primates at ≥3 mg/kg.[1]

[1]. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20.

ALX 5407 is a non-competitive allosteric inhibitor that stabilizes GlyT1 in an inward-open conformation, prolonging synaptic glycine to enhance NMDA receptor function.

Mechanism: Binds extracellular loops of GlyT1, blocking glycine translocation without substrate competition.

Clinical status: Discontinued in Phase I trials for schizophrenia due to dose-limiting cerebellar toxicity in primates.[1]

---

High-affinity glycine transport in neurons and glial cells is a primary means of inactivating synaptic glycine. We have synthesized a potent selective inhibitor of glycine transporter 1 (GlyT1), and characterized its activity using a quail fibroblast cell line (QT6). The glycine transporters GlyT1A, GlyT1B, GlyT1C, and GlyT2 were stably expressed in QT6 cells. The transporters expressed in these cells exhibited appropriate characteristics as described previously for these genes: Na(+)/Cl(-) dependence, appropriate K(m) values for glycine uptake, and appropriate pharmacology, as defined in part by the ability of N-methyl glycine (sarcosine) to competitively inhibit glycine transport. Furthermore, the characteristics of the transporters in the cell lines recapitulate the characteristics of glycine transporters observed in tissue preparations. We developed a sarcosine derivative, (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (ALX 5407), and examined its activity against the cloned glycine transporters. ALX 5407 completely inhibited glycine transport in the GlyT1 cells, with an IC(50) value of 3 nM, but had little or no activity at the human GlyT2 transporter, at other binding sites for glycine, or at other neurotransmitter transporters. The inhibition of glycine transport was essentially irreversible. ALX 5407 represents a novel tool in the investigation of N-methyl-D-aspartate-receptor function. This class of drug may lead to novel therapies in the treatment of schizophrenia. [1]

C24H25CLFNO3

429.91

429.151

200006-08-2

16078946

White to off-white solid powder

5.821

49.77

2

5

9

30

481

1

CN(CC[C@H](C1=CC=C(C=C1)F)OC2=CC=C(C=C2)C3=CC=CC=C3)CC(=O)O.Cl

RPDGSZCYSJWQEE-GNAFDRTKSA-N

InChI=1S/C24H24FNO3.ClH/c1-26(17-24(27)28)16-15-23(20-7-11-21(25)12-8-20)29-22-13-9-19(10-14-22)18-5-3-2-4-6-18;/h2-14,23H,15-17H2,1H3,(H,27,28);1H/t23-;/m1./s1

2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid;hydrochloride

ALX 5407 hydrochloride; 200006-08-2; (+/-)-NFPS hydrochloride; alx-5407 hydrochloride; ALX-5407 (hydrochloride); 2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid;hydrochloride; N-[(3R)-3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine Hydrochloride; ALX5407;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。